phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2020-1-3-10phgenomics-184Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫCURRENT REVIEWПроблемы интеграции медицинской науки, образования и практического здравоохранения: фокус на персонализированную медицинуProblems of integrating medical science, image and practical health care: focus on personalized medicinehttps://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич - д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии 

SPIN-код: 4525-7556

Москва

Sychev Dmitry A. - Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of the Clinical Pharmacology and Therapy

SPIN code: 4525-7556

Moscow

dimasychev@mail.ruhttps://orcid.org/0000-0001-5081-414XМошетоваЛ. К.MoshetovaL. K.

Мошетова Лариса Константиновна - д. м. н., профессор, академик РАН, заведующий кафедрой офтальмологии, президент

SPIN-код: 5697-6825

Москва

Moshetova Larisa K. - MD, Professor, Academician of the Russian Academy of Sciences, Head of the Department of Ophthalmology, President

SPIN code: 5697-6825

Moscow

ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian Federation20202612202001310Copyright © Сычёв Д.А., Мошетова Л.К., 20202020Сычёв Д.А., Мошетова Л.К.Sychev D.A., Moshetova L.K.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/184

На примере технологий персонализации фармакотерапии на основе биомаркеров процессов всасывания, распределения, метаболизма и выведения лекарственных средств (ADME-процессы) представлена методология результатов научных исследований в образовательный процесс в рамках системы непрерывного медицинского образования врачей в реальную клиническую практику. Данная методология разработана и внедрена в Российской медицинской академии непрерывного профессионального образования.

On the example of technologies of personalization of pharmacotherapy based on biomarkers of the processes of absorption, distribution, metabolism and excretion of drugs (ADME-processes), the methodology of the results of scientific research into the educational process within the system of continuous medical education of doctors into the real clinical practice is presented. This methodology has been developed and implemented in the Russian Medical Academy of Continuing Professional Education.

персонализированная медицинапрецизионная медицинафармакогенетикаомиксные технологиинепрерывное медицинское образованиеpersonalized medicineprecision medicinepharmacogeneticsomics technologiescontinuous medical educationReferencesУказ Президента Российской Федерации от 01.12.2016 г. № 642 «О Стратегии научно-технологического развития Российской Федерации». [Decree of the President of the Russian Federation No. 642 of 01.12.2016 «O Strategii nauchno-tekhnologicheskogo razvitiya Rossijskoj Federacii». (In Russ).]. Доступно по: https://clck.ru/SKiCV.Указ Президента Российской Федерации от 01.12.2016 г. № 642 «О Стратегии научно-технологического развития Российской Федерации». [Decree of the President of the Russian Federation No. 642 of 01.12.2016 «O Strategii nauchno-tekhnologicheskogo razvitiya Rossijskoj Federacii». (In Russ).]. Доступно по: https://clck.ru/SKiCV.Выступление Министра Вероники Скворцовой на заседании Совета по стратегическому развитию и приоритетным проектам. [Speech by Minister Veronika Skvortsova at a meeting of the Council for strategic development and priority projects. (In Russ).]. Доступно по: http://medical-science.ru/?p=9056.Выступление Министра Вероники Скворцовой на заседании Совета по стратегическому развитию и приоритетным проектам. [Speech by Minister Veronika Skvortsova at a meeting of the Council for strategic development and priority projects. (In Russ).]. Доступно по: http://medical-science.ru/?p=9056.Приказ Министерства здравоохранения РФ от 24 апреля 2018 г. № 186 «Об утверждении Концепции предиктивной, превентивной и персонализированной медицины». [Order of the Ministry of health of the Russian Federation No. 186 of April 24, 2018 «Ob utverzhdenii Koncepcii prediktivnoj, preventivnoj i personalizirovannoj mediciny». (In Russ).]. Доступно по: https://clck.ru/SKiBe.Приказ Министерства здравоохранения РФ от 24 апреля 2018 г. № 186 «Об утверждении Концепции предиктивной, превентивной и персонализированной медицины». [Order of the Ministry of health of the Russian Federation No. 186 of April 24, 2018 «Ob utverzhdenii Koncepcii prediktivnoj, preventivnoj i personalizirovannoj mediciny». (In Russ).]. Доступно по: https://clck.ru/SKiBe.Указ Президента Российской Федерации от 06.06.2019 г. № 254 «О Стратегии развития здравоохранения в Российской Федерации на период до 2025 года». [Decree of the President of the Russian Federation No. 254 of 06.06.2019 «O Strategii razvitiya zdravoohraneniya v Rossijskoj Federacii na period do 2025 goda». (In Russ).]. Доступно по: https://clck.ru/SKi9e.Указ Президента Российской Федерации от 06.06.2019 г. № 254 «О Стратегии развития здравоохранения в Российской Федерации на период до 2025 года». [Decree of the President of the Russian Federation No. 254 of 06.06.2019 «O Strategii razvitiya zdravoohraneniya v Rossijskoj Federacii na period do 2025 goda». (In Russ).]. Доступно по: https://clck.ru/SKi9e.Personalized Medicine Coalition (PMC). Available from: http://www.personalizedmedicinecoalition.org/Personalized Medicine Coalition (PMC). Available from: http://www.personalizedmedicinecoalition.org/Исследования реальной клинической практики / А.С. Колбин, Д.Ю. Белоусов, С.К. Зырянов, В.В. и др. – М. : Издательство ОКИ : Буки Веди; 2020. – 208 с. [Issledovaniya real’noj klinicheskoj praktiki / AS Kolbin, DYu Belousov, SK Zyryanov et al. Moscow: Publishing OKI : Buki Vedi; 2020. (In Russ).]. Доступно по: https://clck.ru/QkeePИсследования реальной клинической практики / А.С. Колбин, Д.Ю. Белоусов, С.К. Зырянов, В.В. и др. – М. : Издательство ОКИ : Буки Веди; 2020. – 208 с. [Issledovaniya real’noj klinicheskoj praktiki / AS Kolbin, DYu Belousov, SK Zyryanov et al. Moscow: Publishing OKI : Buki Vedi; 2020. (In Russ).]. Доступно по: https://clck.ru/QkeePIvashchenko D, Buromskaya N, Savchenko L et al. Global trigger tool in child psychiatry: Treatment safety evaluation in adolescents with an acute psychotic episode. Int J Risk Saf Med. 2020;31(1):25-35. DOI: 10.3233/JRS-195030.Ivashchenko D, Buromskaya N, Savchenko L et al. Global trigger tool in child psychiatry: Treatment safety evaluation in adolescents with an acute psychotic episode. Int J Risk Saf Med. 2020;31(1):25-35. DOI: 10.3233/JRS-195030.Ivashchenko DV, Rudik AV, Poloznikov AA et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018 Jun 27;33(2):65-73. DOI: 10.1515/dmpt-2017-0036.Ivashchenko DV, Rudik AV, Poloznikov AA et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018 Jun 27;33(2):65-73. DOI: 10.1515/dmpt-2017-0036.Skripka A, Sychev D, Bochkov P et al. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease. High Blood Press Cardiovasc Prev. 2020 Apr;27(2):151-156. DOI: 10.1007/s40292-020-00373-2.Skripka A, Sychev D, Bochkov P et al. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease. High Blood Press Cardiovasc Prev. 2020 Apr;27(2):151-156. DOI: 10.1007/s40292-020-00373-2.Sychev D, Skripka A, Ryzhikova K et al. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019- 0029/dmpt-2019-0029.xml. DOI: 10.1515/dmpt-2019-0029.Sychev D, Skripka A, Ryzhikova K et al. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019- 0029/dmpt-2019-0029.xml. DOI: 10.1515/dmpt-2019-0029.Sychev DA, Levanov AN, Shelekhova TV et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018 Jul 25;11:127-137. DOI: 10.2147/PGPM.S169277.Sychev DA, Levanov AN, Shelekhova TV et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018 Jul 25;11:127-137. DOI: 10.2147/PGPM.S169277.Sychev D, Mirzaev K, Cherniaeva M et al. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Drug Metab Pers Ther. 2020 Sep 4;35(3):/j/ dmdi.2020.35.issue-3/dmpt-2020-0127/dmpt-2020-0127.xml. DOI: 10.1515/dmpt-2020-0127.Sychev D, Mirzaev K, Cherniaeva M et al. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Drug Metab Pers Ther. 2020 Sep 4;35(3):/j/ dmdi.2020.35.issue-3/dmpt-2020-0127/dmpt-2020-0127.xml. DOI: 10.1515/dmpt-2020-0127.Sychev DA, Baturina OA, Mirzaev KB et al. CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. Pharmgenomics Pers Med. 2020 Jan 23;13:29-37. DOI: 10.2147/PGPM.S234910.Sychev DA, Baturina OA, Mirzaev KB et al. CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. Pharmgenomics Pers Med. 2020 Jan 23;13:29-37. DOI: 10.2147/PGPM.S234910.Sychev DA, Vardanyan A, Rozhkov A et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-54. DOI: 10.1089/gtmb.2017.0152.Sychev DA, Vardanyan A, Rozhkov A et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-54. DOI: 10.1089/gtmb.2017.0152.Kryukov AV, Sychev DA, Andreev DA et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018 Mar 22;11:43-49. DOI: 10.2147/PGPM.S157111.Kryukov AV, Sychev DA, Andreev DA et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018 Mar 22;11:43-49. DOI: 10.2147/PGPM.S157111.Sychev DA, Zastrozhin MS, Smirnov VV et al. The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. Pharmgenomics Pers Med. 2016 Sep 14;9:89-95. DOI: 10.2147/PGPM.S110385.Sychev DA, Zastrozhin MS, Smirnov VV et al. The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. Pharmgenomics Pers Med. 2016 Sep 14;9:89-95. DOI: 10.2147/PGPM.S110385.Zastrozhin MS, Brodyansky VM, Skryabin VY et al. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmgenomics Pers Med. 2017 Jul 7;10:209-215. DOI: 10.2147/PGPM.S140700.Zastrozhin MS, Brodyansky VM, Skryabin VY et al. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmgenomics Pers Med. 2017 Jul 7;10:209-215. DOI: 10.2147/PGPM.S140700.Sychev DA, Zastrozhin MS, Miroshnichenko II et al. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. Drug Metab Pers Ther. 2017 Sep 26;32(3):129-136. DOI: 10.1515/dmpt-2017-0021.Sychev DA, Zastrozhin MS, Miroshnichenko II et al. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. Drug Metab Pers Ther. 2017 Sep 26;32(3):129-136. DOI: 10.1515/dmpt-2017-0021.Zastrozhin MS, Grishina EA, Ryzhikova KA et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmgenomics Pers Med. 2017 Dec 28;11:1-5. DOI: 10.2147/PGPM.S144503.Zastrozhin MS, Grishina EA, Ryzhikova KA et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmgenomics Pers Med. 2017 Dec 28;11:1-5. DOI: 10.2147/PGPM.S144503.Zastrozhin MS, Grishina EA, Denisenko NP et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. DOI: 10.2147/PGPM.S160763.Zastrozhin MS, Grishina EA, Denisenko NP et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. DOI: 10.2147/PGPM.S160763.Zastrozhin MS, Antonenko AP, Nesterenko EV et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochl orophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018 Dec 19;33(4):187–194. DOI: 10.1515/dmpt-2018-0019.Zastrozhin MS, Antonenko AP, Nesterenko EV et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochl orophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018 Dec 19;33(4):187–194. DOI: 10.1515/dmpt-2018-0019.Zastrozhin MS, Skryabin VY, Smirnov VV et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Can J Physiol Pharmacol. 2019 Aug;97(8):781–785. DOI: 10.1139/cjpp-2019-0177.Zastrozhin MS, Skryabin VY, Smirnov VV et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Can J Physiol Pharmacol. 2019 Aug;97(8):781–785. DOI: 10.1139/cjpp-2019-0177.Zastrozhin MS, Skryabin VY, Torrado M et al. Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. Pharmacogenomics. 2020 Jan;21(2):111-123. DOI: 10.2217/pgs-2019-0019.Zastrozhin MS, Skryabin VY, Torrado M et al. Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. Pharmacogenomics. 2020 Jan;21(2):111-123. DOI: 10.2217/pgs-2019-0019.Skryabin VY, Zastrozhin MS, Torrado MV et al. How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome? Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019-0026/dmpt-2019-0026.xml. DOI: 10.1515/dmpt-2019-0026.Skryabin VY, Zastrozhin MS, Torrado MV et al. How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome? Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019-0026/dmpt-2019-0026.xml. DOI: 10.1515/dmpt-2019-0026.Zastrozhin MS, Skryabin VY, Sorokin AS et al. CYP3A subfamily activity affects the equilibrium concentration of Phenazepam® in patients with anxiety disorders and comorbid alcohol use disorder. Pharmacogenomics. 2020 May;21(7):449-457. DOI: 10.2217/pgs-2019-0071.Zastrozhin MS, Skryabin VY, Sorokin AS et al. CYP3A subfamily activity affects the equilibrium concentration of Phenazepam® in patients with anxiety disorders and comorbid alcohol use disorder. Pharmacogenomics. 2020 May;21(7):449-457. DOI: 10.2217/pgs-2019-0071.Rytkin E, Mirzaev KB, Grishina EA et al. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients? Pharmgenomics Pers Med. 2017 Sep 18;10:243–245. DOI: 10.2147/PGPM.S143250.Rytkin E, Mirzaev KB, Grishina EA et al. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients? Pharmgenomics Pers Med. 2017 Sep 18;10:243–245. DOI: 10.2147/PGPM.S143250.Mirzaev KB, Rytkin E, Ryzhikova KA et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metab Pers Ther. 2018 Sep 25;33(3):109-118. DOI: 10.1515/dmpt-2018-0006.Mirzaev KB, Rytkin E, Ryzhikova KA et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metab Pers Ther. 2018 Sep 25;33(3):109-118. DOI: 10.1515/dmpt-2018-0006.Mirzaev KB, Samsonova KI, Potapov PP et al. Genotyping and phenotyping CYP3A4CYP3A5: no association with antiplatelet effect of clopidogrel. Mol Biol Rep. 2019 Aug;46(4):4195–4199. DOI: 10.1007/s11033-019-04871-y.Mirzaev KB, Samsonova KI, Potapov PP et al. Genotyping and phenotyping CYP3A4CYP3A5: no association with antiplatelet effect of clopidogrel. Mol Biol Rep. 2019 Aug;46(4):4195–4199. DOI: 10.1007/s11033-019-04871-y.Mirzaev KB, Osipova DV, Kitaeva EJ et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther. 2019 Sep 27;34(3):/j/ dmdi.2019.34.issue-3/dmpt-2018-0039/dmpt-2018-0039.xml. DOI: 10.1515/dmpt-2018-0039.Mirzaev KB, Osipova DV, Kitaeva EJ et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther. 2019 Sep 27;34(3):/j/ dmdi.2019.34.issue-3/dmpt-2018-0039/dmpt-2018-0039.xml. DOI: 10.1515/dmpt-2018-0039.Denisenko NP, Sychev DA, Sizova ZM et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmgenomics Pers Med. 2017 Sep 27;10:253–259. DOI: 10.2147/PGPM.S141935.Denisenko NP, Sychev DA, Sizova ZM et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmgenomics Pers Med. 2017 Sep 27;10:253–259. DOI: 10.2147/PGPM.S141935.Denisenko NP, Sychev DA, Sizova ZM et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. Pharmgenomics Pers Med. 2018 Jun 18;11:107–112. DOI: 10.2147/PGPM.S159708.Denisenko NP, Sychev DA, Sizova ZM et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. Pharmgenomics Pers Med. 2018 Jun 18;11:107–112. DOI: 10.2147/PGPM.S159708.Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics. 2019 Jul;20(11):847-865. DOI: 10.2217/pgs-2019-0013.Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics. 2019 Jul;20(11):847-865. DOI: 10.2217/pgs-2019-0013.Sychev DA, Ivashchenko DV, Rusin IV. [Impact of pharmacogenetic testing on the risk of bleedings and excessive hypocoagulation episodes in the use of warfarin: the first meta-analysis of Russian prospective studies]. Ter Arkh. 2014;86(4):64–71.Sychev DA, Ivashchenko DV, Rusin IV. [Impact of pharmacogenetic testing on the risk of bleedings and excessive hypocoagulation episodes in the use of warfarin: the first meta-analysis of Russian prospective studies]. Ter Arkh. 2014;86(4):64–71.Denisenko NP, Sychev DA, Sizova ZM et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple eradication therapy in slavic patients with peptic ulcers: a meta-analysis. Eksp Klin Gastroenterol. 2016;(11):11–16.Denisenko NP, Sychev DA, Sizova ZM et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple eradication therapy in slavic patients with peptic ulcers: a meta-analysis. Eksp Klin Gastroenterol. 2016;(11):11–16.Rytkin EI, Mirzaev KB, Bure IV, Sychev DA. [Micro-RNA as a new biomarker of activity of the cytochrome system P-450: significance for predicting the antiplatelet action of P2Y12 receptor inhibitors]. Ter Arkh. 2019 Aug 15;91(8):115–117. DOI: 10.26442/00403660.2019.08.000389.Rytkin EI, Mirzaev KB, Bure IV, Sychev DA. [Micro-RNA as a new biomarker of activity of the cytochrome system P-450: significance for predicting the antiplatelet action of P2Y12 receptor inhibitors]. Ter Arkh. 2019 Aug 15;91(8):115–117. DOI: 10.26442/00403660.2019.08.000389.Zastrozhin MS, Skryabin VY, Smirnov VV et al. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. Gene. 2020 May 20;739:144513. DOI: 10.1016/j.gene.2020.144513.Zastrozhin MS, Skryabin VY, Smirnov VV et al. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. Gene. 2020 May 20;739:144513. DOI: 10.1016/j.gene.2020.144513.Rytkin E, Mirzaev KB, Bure IV, Sychev DA. Selection of miRNAs for clopidogrel resistance prediction. Meta Gene. September 2020; 25:100745. DOI: 10.1016/j.mgene.2020.100745.Rytkin E, Mirzaev KB, Bure IV, Sychev DA. Selection of miRNAs for clopidogrel resistance prediction. Meta Gene. September 2020; 25:100745. DOI: 10.1016/j.mgene.2020.100745.Mirzaev KB, Zelenskaya EM, Barbarash OL et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med. 2017 Apr 12;10:107– 114. DOI: 10.2147/PGPM.S126305.Mirzaev KB, Zelenskaya EM, Barbarash OL et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med. 2017 Apr 12;10:107– 114. DOI: 10.2147/PGPM.S126305.Mirzaev KB, Sychev DA, Ryzhikova KA et al. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genet Test Mol Biomarkers. 2017 Dec;21(12):747–753. DOI: 10.1089/gtmb.2017.0036.Mirzaev KB, Sychev DA, Ryzhikova KA et al. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genet Test Mol Biomarkers. 2017 Dec;21(12):747–753. DOI: 10.1089/gtmb.2017.0036.Fedorinov DS, Mirzaev KB, Ivashchenko DV et al. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 Jun 27;33(2):91–98. DOI: 10.1515/dmpt-2018-0004.Fedorinov DS, Mirzaev KB, Ivashchenko DV et al. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 Jun 27;33(2):91–98. DOI: 10.1515/dmpt-2018-0004.Sychev DA, Abdullaev SP, Mirzaev KB et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep. 2019 Jun;46(3):2761–2769. DOI: 10.1007/s11033-019-04722-w.Sychev DA, Abdullaev SP, Mirzaev KB et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep. 2019 Jun;46(3):2761–2769. DOI: 10.1007/s11033-019-04722-w.Abdullaev SP, Mirzaev KB, Burashnikova IS et al. Clinically relevant pharmacogenetic markers in Tatars and Balkars. Mol Biol Rep. 2020 May;47(5):3377–3387. DOI: 10.1007/s11033-020-05416-4.Abdullaev SP, Mirzaev KB, Burashnikova IS et al. Clinically relevant pharmacogenetic markers in Tatars and Balkars. Mol Biol Rep. 2020 May;47(5):3377–3387. DOI: 10.1007/s11033-020-05416-4.Mirzaev K, Abdullaev S, Akmalova K et al. Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. Pharmacogenomics. 2020 Jul;21(10):677–694. DOI: 10.2217/pgs-2020-0005.Mirzaev K, Abdullaev S, Akmalova K et al. Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. Pharmacogenomics. 2020 Jul;21(10):677–694. DOI: 10.2217/pgs-2020-0005.Abdullaev SP, Mirzaev KB, Sychev DA. [Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation]. Ter Arkh. 2019 Aug 15;91(8):22–27. DOI: 10.26442/00403660.2019.08.000379.Abdullaev SP, Mirzaev KB, Sychev DA. [Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation]. Ter Arkh. 2019 Aug 15;91(8):22–27. DOI: 10.26442/00403660.2019.08.000379.Zastrozhin MS, Sorokin AS, Agibalova TV et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Hum Psychopharmacol. 2018 Nov;33(6):e2677. DOI: 10.1002/hup.2677.Zastrozhin MS, Sorokin AS, Agibalova TV et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Hum Psychopharmacol. 2018 Nov;33(6):e2677. DOI: 10.1002/hup.2677.Zastrozhin M, Skryabin V, Sorokin A et al. Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. Drug Metab Pers Ther. 2020 Sep 1:/j/ dmdi.ahead-of-print/dmdi-2019-0033/dmdi-2019-0033.xml. DOI: 10.1515/dmpt-2019-0033.Zastrozhin M, Skryabin V, Sorokin A et al. Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. Drug Metab Pers Ther. 2020 Sep 1:/j/ dmdi.ahead-of-print/dmdi-2019-0033/dmdi-2019-0033.xml. DOI: 10.1515/dmpt-2019-0033.Острый коронарный синдром без подъёма сегмента ST на электрокардиограмме. Клинические рекомендации (2020). [Ostryj koronarnyj sindrom bez pod»yoma segmenta ST na elektrokardiogramme. Klinicheskie rekomendacii (2020). (In Russ).]. Доступно по: https://clck.ru/SKiFWОстрый коронарный синдром без подъёма сегмента ST на электрокардиограмме. Клинические рекомендации (2020). [Ostryj koronarnyj sindrom bez pod»yoma segmenta ST na elektrokardiogramme. Klinicheskie rekomendacii (2020). (In Russ).]. Доступно по: https://clck.ru/SKiFWПриказ Минтруда РФ от 31.07.2020 № 477н «Об утверждении профессионального стандарта «врач – клинический фармаколог». [Order of the Ministry of labor of the Russian Federation No. 477n of 31.07.2020 «Ob utverzhdenii professional’nogo standarta «vrach – klinicheskij farmakolog». (In Russ).]. Доступно по: https://minjust.consultant.ru/special/documents/document/47018Приказ Минтруда РФ от 31.07.2020 № 477н «Об утверждении профессионального стандарта «врач – клинический фармаколог». [Order of the Ministry of labor of the Russian Federation No. 477n of 31.07.2020 «Ob utverzhdenii professional’nogo standarta «vrach – klinicheskij farmakolog». (In Russ).]. Доступно по: https://minjust.consultant.ru/special/documents/document/47018Атлас новых профессий. [Atlas novyh professij. (In Russ).]. Доступно по: http://atlas100.ru.Атлас новых профессий. [Atlas novyh professij. (In Russ).]. Доступно по: http://atlas100.ru.Российская медицинская академия непрерывного профессионального образования. [Russian Medical Academy of Continuous Professional Education. (In Russ).]. Доступно по: https://rmapo.ru.Российская медицинская академия непрерывного профессионального образования. [Russian Medical Academy of Continuous Professional Education. (In Russ).]. Доступно по: https://rmapo.ru.Mirzaev KB, Kiselev Y, Ivashchenko DV et al. Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. Br J Clin Pharmacol. 2020 Aug 30;1–5. DOI: 10.1111/bcp.14526.Mirzaev KB, Kiselev Y, Ivashchenko DV et al. Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. Br J Clin Pharmacol. 2020 Aug 30;1–5. DOI: 10.1111/bcp.14526.

The authors declare that there are no conflicts of interest present.